Hiligsmann Mickaël, Bruyère Olivier
Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht - The Netherlands.
WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège - Belgium.
Glob Reg Health Technol Assess. 2024 Apr 3;11:75-81. doi: 10.33393/grhta.2024.2682. eCollection 2024 Jan-Dec.
Osteoarthritis (OA) is a degenerative joint disease with a substantial global burden, causing chronic pain and reduced quality of life. Managing OA efficiently while maximizing healthcare resources is crucial. Health economics and health technology assessment (HTA) are central tools providing a framework to evaluate the clinical, economic, and ethical aspects of healthcare technologies and interventions. This article presents some insights into the role of health economics and the HTA process in OA management. It also illustrates an example of cost-effectiveness analysis in a specific healthcare context, on the basis of a recent clinical trial involving hyaluronic acid treatment for knee OA. While HTA offers valuable insights, it faces challenges like data availability and resource constraints. Integrating health economics into decision-making can enhance patient care and allocate resources effectively in OA and other healthcare domains.
骨关节炎(OA)是一种具有重大全球负担的退行性关节疾病,会导致慢性疼痛并降低生活质量。在最大限度利用医疗资源的同时有效管理骨关节炎至关重要。卫生经济学和卫生技术评估(HTA)是核心工具,提供了一个框架来评估医疗技术和干预措施的临床、经济和伦理方面。本文介绍了卫生经济学和HTA流程在骨关节炎管理中的作用的一些见解。它还基于最近一项涉及透明质酸治疗膝骨关节炎的临床试验,举例说明了在特定医疗背景下的成本效益分析。虽然HTA提供了有价值的见解,但它面临着数据可用性和资源限制等挑战。将卫生经济学纳入决策可以改善骨关节炎及其他医疗领域的患者护理并有效分配资源。